RayKnowChina Research Map
Shortlist0

Not yet recruitingHepatocellular carcinomaPhase 2

Registered title, quoted from ClinicalTrials.gov

SBRT Combined With Iparomlimab and Tuvonralimab (QL1706) and Bevacizumab for Hepatocellular Carcinoma

An open trial on hepatocellular carcinoma, registered on ClinicalTrials.gov. Led by Peking University Cancer Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking University Cancer Hospital北京大学肿瘤医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07882056, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 8

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (8 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Histologically or radiologically confirmed hepatocellular carcinoma.

    Inclusion criterion 2

  3. Child-Pugh class A or B (score <=7).

    Inclusion criterion 9

    Poor liver function: Child-Pugh score >7, or hepatic enzymes, coagulation, bilirubin, or bone marrow function not meeting the enrollment criteria.

    Exclusion criterion 3

  4. Inoperable disease, not a transplant candidate, and unsuitable for ablation or transarterial therapy, including locally advanced and oligometastatic disease. 4.1 Locally advanced: no extrahepatic metastasis; portal vein, hepatic vein, or inferior vena cava tumor thrombus permitted. 4.2 Oligometastatic: a limited number (<=5) of extrahepatic metastatic lesions (lymph node, visceral, bone, adrenal, or soft tissue; brain metastases excluded), with or without intrahepatic disease meeting the locally advanced definition. Vascular invasion is not counted in the lesion number, and lesions achieving complete response (per RECIST 1.1) after prior therapy are not counted.

    Inclusion criterion 4

    No prior systemic therapy, or progression or intolerance after first-line systemic therapy, with more than 3 weeks since the last dose.

    Inclusion criterion 7

    Prior selective internal radiation therapy or yttrium-90 hepatic arterial therapy.

    Exclusion criterion 8

  5. ECOG performance status 0-1 within 1 week before enrollment.

    Inclusion criterion 8

    ECOG performance status >=2.

    Exclusion criterion 2

  6. Hematology: hemoglobin >=90 g/L; white blood cell count >=3.0 x 10\^9/L; absolute neutrophil count >=1.5 x 10\^9/L; platelet count >=75 x 10\^9/L.

    Inclusion criterion 10

    ALT and AST <=5 x upper limit of normal (ULN); alkaline phosphatase <=5 x ULN; total bilirubin <=3 x ULN; albumin >=28 g/L.

    Inclusion criterion 12

    Serum creatinine <=1.5 x ULN, or creatinine clearance >=50 mL/min calculated by the Cockcroft-Gault formula.

    Inclusion criterion 13

  7. At least one measurable lesion per RECIST 1.1.

    Inclusion criterion 5

  8. Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).

    Exclusion criterion 19

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07882056, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age >= 18 years, male or female.
  • Histologically or radiologically confirmed hepatocellular carcinoma.
  • Barcelona Clinic Liver Cancer (BCLC) stage B or C.
  • Inoperable disease, not a transplant candidate, and unsuitable for ablation or transarterial therapy, including locally advanced and oligometastatic disease. 4.1 Locally advanced: no extrahepatic metastasis; portal vein, hepatic vein, or inferior vena cava tumor thrombus permitted. 4.2 Oligometastatic: a limited number (<=5) of extrahepatic metastatic lesions (lymph node, visceral, bone, adrenal, or soft tissue; brain metastases excluded), with or without intrahepatic disease meeting the locally advanced definition. Vascular invasion is not counted in the lesion number, and lesions achieving complete response (per RECIST 1.1) after prior therapy are not counted.
  • At least one measurable lesion per RECIST 1.1.
  • All lesions can safely receive stereotactic body radiotherapy.
  • No prior systemic therapy, or progression or intolerance after first-line systemic therapy, with more than 3 weeks since the last dose.
  • ECOG performance status 0-1 within 1 week before enrollment.
  • Child-Pugh class A or B (score <=7).
  • Hematology: hemoglobin >=90 g/L; white blood cell count >=3.0 x 10\^9/L; absolute neutrophil count >=1.5 x 10\^9/L; platelet count >=75 x 10\^9/L.
  • INR <=2.3, or prothrombin time exceeding the upper limit of normal by <=6 seconds.
  • ALT and AST <=5 x upper limit of normal (ULN); alkaline phosphatase <=5 x ULN; total bilirubin <=3 x ULN; albumin >=28 g/L.
  • Serum creatinine <=1.5 x ULN, or creatinine clearance >=50 mL/min calculated by the Cockcroft-Gault formula.
  • Urine protein <2+ (patients with urine protein >=2+ may undergo 24-hour urine protein quantification and are eligible if the 24-hour urine protein is <1.0 g).
  • Patients with active hepatitis B virus (HBV) infection: HBV-DNA <500 IU/mL (or <2500 copies/mL if only copy/mL is available) and willingness to receive antiviral therapy throughout the study; patients positive for hepatitis C virus (HCV) RNA must receive standard antiviral therapy, with hepatic enzyme elevation <=CTCAE grade 1.
  • Women of childbearing potential (generally 15-49 years) must have a negative serum or urine pregnancy test within 14 days before enrollment and be willing to use adequate contraception during the study and for 8 weeks after the last dose of study drug; men must be surgically sterile or agree to adequate contraception during the study and for 8 weeks after the last dose.
  • Voluntary participation with signed informed consent, good compliance, and willingness to undergo follow-up.

Exclusion Criteria:

  • Age <18 years.
  • ECOG performance status >=2.
  • Poor liver function: Child-Pugh score >7, or hepatic enzymes, coagulation, bilirubin, or bone marrow function not meeting the enrollment criteria.
  • Hepatic encephalopathy, massive ascites, or abdominal infection within 1 month.
  • Brain metastases.
  • Malignant pleural effusion.
  • Prior radiotherapy to any site requiring treatment in this study (risk of field overlap causing excessive irradiation of normal tissue).
  • Prior selective internal radiation therapy or yttrium-90 hepatic arterial therapy.
  • Tumor directly invading the stomach, duodenum, small intestine, or large intestine; or tumor within 3 mm of the spinal cord.
  • Maximum diameter of any single lesion >15 cm.
  • Sum of the maximum diameters of all intrahepatic lesions, or the maximum diameter of a single confluent lesion, >20 cm.
  • More than 5 discrete intrahepatic HCC lesions.
  • Normal liver volume <700 mL.
  • Known history of allogeneic organ or hematopoietic stem cell transplantation, or planned transplantation.
  • Known allergy to iparomlimab and tuvonralimab, bevacizumab, or drug excipients, or severe hypersensitivity to any other monoclonal antibody.
  • Live attenuated vaccination within 4 weeks before the first dose or planned during the study.
  • Severe active autoimmune disease.
  • Any other malignancy, except adequately treated basal cell or squamous cell skin carcinoma or cervical carcinoma in situ.
  • Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS).
  • Within 6 months before enrollment: myocardial infarction, severe or unstable angina, NYHA class >=2 heart failure, poorly controlled arrhythmia, or symptomatic congestive heart failure.
  • Coagulation abnormality with bleeding tendency, or currently receiving thrombolytic, anticoagulant, or antiplatelet therapy.
  • Known hereditary or acquired bleeding or thrombotic tendency, such as hemophilia, coagulation disorders, or severe thrombocytopenia.
  • Risk of gastrointestinal bleeding, including: (1) active peptic ulcer; (2) melena or hematemesis within 1 month; (3) gastroscopy showing ulcer or bleeding lesions, esophagogastric varices with red color signs (+), or variceal diameter >1 cm. Also: history of psychotropic drug abuse or drug addiction, or other severe medical or psychiatric illness, or laboratory abnormality that may increase study risk, confound results, or render the patient unsuitable in the investigator's judgment.

Quoted from ClinicalTrials.gov, NCT07882056, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07882056, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07882056